dc.relation.references | 1. Jarius S, Wildemann B. The history of neuromyelitis optica. J
Neuroinflammation. 2013;10(1):1–12.
2. De Seze J. Neuromyelitis optica. Arch Neurol [Internet]. 2003 Sep
1;60(9):1336–8. Available from:
http://archneur.jamanetwork.com/article.aspx?doi=10.1001/archneur.
60.9.1336
3. Brain WR. Critical review: Disseminated sclerosis. Qjm [Internet].
1930 Apr 1;os-23(91):343–91. Available from:
https://academic.oup.com/qjmed/articlelookup/doi/10.1093/qjmed/os-23.91.343
4. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG.
The clinical course of neuromyelitis optica (Devic’s syndrome).
Neurology [Internet]. 1999 Sep 1;53(5):1107–14. Available from:
https://www.neurology.org/lookup/doi/10.1212/WNL.53.5.1107
5. Lennon PVA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti
CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis
optica: Distinction from multiple sclerosis. Lancet.
2004;364(9451):2106–12.
6. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF,
79
Weinshenker BG. Revised diagnostic criteria for neuromyelitis
optica. Neurology [Internet]. 2006 May 23;66(10):1485–9. Available
from:
https://www.neurology.org/lookup/doi/10.1212/01.wnl.0000216139.4
4259.74
7. Bennett JL. Finding NMO: The Evolving Diagnostic Criteria of
Neuromyelitis Optica. J Neuro-Ophthalmology [Internet]. 2016
Sep;36(3):238–45. Available from:
https://journals.lww.com/00041327-201609000-00003
8. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis
T, et al. International consensus diagnostic criteria for neuromyelitis
optica spectrum disorders. Neurology. 2015;85(2):177–89.
9. Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et
al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its
Prevalence and Incidence Worldwide. Front Neurol.
2020;11(June):1–13.
10. Asgari N, Lillevang ST, Skejoe HPB, Falah M, Stenager E, Kyvik
KO. A population-based study of neuromyelitis optica in Caucasians.
Neurology. 2011;76(18):1589–95.
11. Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ,
80
Majed M, et al. Epidemiology of aquaporin-4 autoimmunity and
neuromyelitis optica spectrum. Ann Neurol. 2016 May 1;79(5):775–
83.
12. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M.
Epidemiology of neuromyelitis optica in the United States: A
multicenter analysis. Arch Neurol. 2012;69(9):1176–80.
13. Collongues N, Marignier R, Zéphir H, Papeix C, Blanc F, Ritleng C,
et al. Neuromyelitis optica in France: A multicenter study of 125
patients. Neurology. 2010;74(9):736–42.
14. Cabrera-Gómez JA, Kurtzke JF, González-Quevedo A, LaraRodríguez R. An epidemiological study of neuromyelitis optica in
Cuba. J Neurol [Internet]. 2009 Jan 9;256(1):35–44. Available from:
http://link.springer.com/10.1007/s00415-009-0009-0
15. Alvarenga MP, Schimidt S, Alvarenga RP. Epidemiology of
neuromyelitis optica in Latin America. Mult Scler J - Exp Transl
Clin. 2017;3(3).
16. Rivera VM, Hamuy F, Rivas V, Gracia F, Rojas JI, Bichuetti DB, et
al. Status of the neuromyelitis optica spectrum disorder in Latin
America. Mult Scler Relat Disord. 2021;53.
17. Pereira FFCC, Pereira ABC, Alvarenga RMP, Vasconcelos CCF. The
81
prevalence of Neuromyelitis optica in a Brazilian City. J Neurol Sci
[Internet]. 2015 Oct;357:e207. Available from:
https://linkinghub.elsevier.com/retrieve/pii/S0022510X15012101
18. Lana-Peixoto MA, Talim NC, Pedrosa D, Macedo JM, SantiagoAmaral J. Prevalence of neuromyelitis optica spectrum disorder in
Belo Horizonte, Southeast Brazil. Mult Scler Relat Disord.
2021;50(November 2020).
19. Silva GD, Apóstolos-Pereira SL, Callegaro D. Estimated prevalence
of AQP4 positive neuromyelitis optica spectrum disorder and MOG
antibody associated disease in São Paulo, Brazil. Mult Scler Relat
Disord. 2023;70(December 2022):2022–4.
20. Alves CS, Santos FBC, Diniz DS. Correlation between Amerindian
ancestry and neuromyelitis optica spectrum disorders (NMSOD)
among patients in Midwestern Brazil. Arq Neuropsiquiatr.
2022;80(5):497–504.
21. Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, et al.
Racial differences in neuromyelitis optica spectrum disorder.
Neurology. 2018;91(22):E2089–99.
22. Wu Y, Zhong L, Geng J. Neuromyelitis optica spectrum disorder:
Pathogenesis, treatment, and experimental models. Mult Scler Relat
82
Disord [Internet]. 2019 Jan;27:412–8. Available from:
https://linkinghub.elsevier.com/retrieve/pii/S2211034818305303
23. Frigeri A, Gropper MA, Umenishi F, Kawashima M, Brown D,
Verkman AS. Localization of MIWC and GLIP water channel
homologs in neuromuscular, epithelial and glandular tissues. J Cell
Sci [Internet]. 1995 Sep 1;108(9):2993–3002. Available from:
https://journals.biologists.com/jcs/article/108/9/2993/24600/Localizat
ion-of-MIWC-and-GLIP-water-channel
24. Ratelade J, Verkman AS. Neuromyelitis optica: Aquaporin-4 based
pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol
[Internet]. 2012 Sep;44(9):1519–30. Available from:
https://linkinghub.elsevier.com/retrieve/pii/S1357272512002129
25. Carnero Contentti E, Correale J. Neuromyelitis optica spectrum
disorders: from pathophysiology to therapeutic strategies. J
Neuroinflammation. 2021;18(1):1–18.
26. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA,
Weinshenker BG. A secondary progressive clinical course is
uncommon in neuromyelitis optica. Neurology [Internet]. 2007 Feb
20;68(8):603–5. Available from:
https://www.neurology.org/lookup/doi/10.1212/01.wnl.0000254502.8
7233.9a
83
27. Papais-Alvarenga RM, Carellos SC, Alvarenga MP, Holander C,
Bichara RP, Thuler LCS. Clinical course of optic neuritis in patients
with relapsing neuromyelitis optica. Arch Ophthalmol [Internet].
2008 Jan 1;126(1):12–6. Available from:
http://archopht.jamanetwork.com/article.aspx?doi=10.1001/archophth
almol.2007.26
28. Dutra BG, Da Rocha AJ, Nunes RH, Maia ACM. Neuromyelitis
optica spectrum disorders: Spectrum of MR imaging findings and
their differential diagnosis. Radiographics. 2018;38(1):169–93.
29. Merle H, Olindo S, Donnio A, Richer R, Smadja D, Cabre P. Retinal
peripapillary nerve fiber layer thickness in neuromyelitis optica.
Investig Ophthalmol Vis Sci [Internet]. 2008 Oct 1;49(10):4412–7.
Available from:
http://iovs.arvojournals.org/article.aspx?doi=10.1167/iovs.08-1815
30. Flanagan EP, Weinshenker BG, Krecke KN, Lennon VA, Lucchinetti
CF, McKeon A, et al. Short Myelitis Lesions in Aquaporin-4-IgG–
Positive Neuromyelitis Optica Spectrum Disorders. JAMA Neurol
[Internet]. 2015 Jan 1;72(1):81. Available from:
http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jamaneur
ol.2014.2137
31. Sato D, Fujihara K. Atypical presentations of neuromyelitis optica.
84
Arq Neuropsiquiatr. 2011;69(5):824–8.
32. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable
hiccup and nausea with periaqueductal lesions in neuromyelitis
optica. Neurology. 2005;65(9):1479–82.
32. Takahashi T, Miyazawa I, Misu T, Takano R, Nakashima I, Fujihara
K, et al. Intractable hiccup and nausea in neuromyelitis optica with
anti-aquaporin-4 antibody: A herald of acute exacerbations. J Neurol
Neurosurg Psychiatry. 2008;79(9):1075–8.
33. Iorio R, Lucchinetti CF, Lennon VA, Farrugia G, Pasricha PJ,
Weinshenker BG, et al. Intractable Nausea and Vomiting From
Autoantibodies Against a Brain Water Channel. Clin Gastroenterol
Hepatol [Internet]. 2013 Mar;11(3):240–5. Available from:
https://linkinghub.elsevier.com/retrieve/pii/S1542356512014218
34. Hyun JW, Kwon YN, Kim SM, Lee HL, Jeong WK, Lee HJ, et al.
Value of Area Postrema Syndrome in Differentiating Adults With
AQP4 vs. MOG Antibodies. Front Neurol. 2020;11.
35. Okada K, Kobata M, Naruke S. Neuromyelitis optica spectrum
disorder with area postrema syndrome. Neurol Clin Pract [Internet].
2019 Apr;9(2):173–5. Available from:
https://cp.neurology.org/lookup/doi/10.1212/CPJ.0000000000000586
85
36. Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, et al.
Brainstem manifestations in neuromyelitis optica: a multicenter study
of 258 patients. Mult Scler J [Internet]. 2014 Jun 7;20(7):843–7.
Available from:
http://journals.sagepub.com/doi/10.1177/1352458513507822
37. Etemadifar M, Nouri H, Khorvash R, Salari M, Ghafari K,
Aghababaee A. Frequency of diencephalic syndrome in NMOSD.
Acta Neurol Belg [Internet]. 2022 Aug 13;122(4):961–7. Available
from: https://link.springer.com/10.1007/s13760-021-01792-1
38. Kim W, Kim SH, Hyun Lee S, Feng Li X, Jin Kim H. Brain
abnormalities as an initial manifestation of neuromyelitis optica
spectrum disorder. Mult Scler J. 2011;17(9):1107–12.
39. Cabre P. Do modern therapies change natural history of
Neuromyelitis optica? Rev Neurol (Paris) [Internet].
2021;177(5):567–70. Available from:
https://doi.org/10.1016/j.neurol.2020.07.002
40. Queiroz ALG de, Soares Neto HR, Kobayashi TT, Silva SMC de A.
Plasma exchange in inflammatory demyelinating disorders of the
central nervous system: reasonable use in the clinical practice. Arq
Neuropsiquiatr [Internet]. 2023 Mar 14;81(03):296–307. Available
from: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-
86
1758447
41. Bichuetti DB, Perin MM de M, Souza NA de, Oliveira EML de.
Treating neuromyelitis optica with azathioprine: 20-year clinical
practice. Mult Scler J [Internet]. 2019 Jul 15;25(8):1150–61.
Available from:
http://journals.sagepub.com/doi/10.1177/1352458518776584
42. Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, et
al. Safety and efficacy of rituximab in neuromyelitis optica spectrum
disorders (RIN-1 study): a multicentre, randomised, double-blind,
placebo-controlled trial. Lancet Neurol [Internet]. 2020;19(4):298–
306. Available from: http://dx.doi.org/10.1016/S1474-
4422(20)30066-1
43. Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ,
Wingerchuk DM, et al. Inebilizumab for the treatment of
neuromyelitis optica spectrum disorder (N-MOmentum): a doubleblind, randomised placebo-controlled phase 2/3 trial. Lancet
[Internet]. 2019;394(10206):1352–63. Available from:
http://dx.doi.org/10.1016/S0140-6736(19)31817-3
44. Duchow A, Bellmann-Strobl J. Satralizumab in the treatment of
neuromyelitis optica spectrum disorder. Neurodegener Dis Manag
[Internet]. 2021 Feb;11(1):49–59. Available from:
87
https://www.futuremedicine.com/doi/10.2217/nmt-2020-0046
45. Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al.
Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum
disorder. N Engl J Med. 2019;381(7):614–25.
46. Pittock SJ, Barnett M, Bennett JL, Berthele A, de Sèze J, Levy M, et
al. Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica
Spectrum Disorder. Ann Neurol [Internet]. 2023 Apr 5; Available
from: https://onlinelibrary.wiley.com/doi/10.1002/ana.26626
47. JF K. Rating neurologic impairment in multiple sclerosis: an
expanded disability status scale (EDSS). Neurology.
1983;Nov;33(11):1444-52.
48. Cendrowski WS. Progression index and disability status in multiple
sclerosis: a resurvey of 207 patients in central Poland. Schweiz Arch
Neurol Psychiatr [Internet]. 1986;137(4):5–13. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/2428106
49. Bichuetti DB, Oliveira EML, Souza NA, Rivero RLM, Gabbai AA.
Neuromyelitis optica in Brazil: A study on clinical and prognostic
factors. Mult Scler. 2009;
50. Etemadifar M, Dashti M, Vosoughi R, Abtahi SH, Ramagopalan S
V., Nasr Z. An epidemiological study of neuromyelitis optica in
88
Isfahan. Mult Scler J. 2014;20(14):1920–2.
51. Del Negro MC, Marinho PBC, Papais-Alvarenga RM. Neuromyelitis
optica: phenotypic characteristics in a Brazilian case series. Arq
Neuropsiquiatr. 2017;75(2):81–6.
52. Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace
J, et al. MRI characteristics of neuromyelitis optica spectrum
disorder: An international update. Neurology. 2015;
53. Bukhari W, Clarke L, O’Gorman C, Khalilidehkordi E, Arnett S,
Prain KM, et al. The clinical profile of NMOSD in Australia and New
Zealand. J Neurol [Internet]. 2020;267(5):1431–43. Available from:
https://doi.org/10.1007/s00415-020-09716-4
54. Maria A, Zanette D, Gonc MDS, Bahia S, Vasconcelos L, Nogueira
A, et al. SICKLE CELL ANEMIA : DELAYED DIAGNOSIS IN
BAHIA , BRAZIL - … the results of neonatal screening have shown
that in Bahia , 1 in 650 children are born each year with SCD , a
higher prevalence than any. Ethn Dis. 2011;21(71):243–7.
55. Domingos J, Isidoro L, Figueiredo R, Brum M, Capela C, Barros P, et
al. Neuromyelitis optica in Portugal (NEMIPORT) - A multicentre
study. Clin Neurol Neurosurg [Internet]. 2015;134:79–84. Available
from: http://dx.doi.org/10.1016/j.clineuro.2015.04.001
89
56. Amaral JM, Talim N, Kleinpaul R, Lana-Peixoto MA. Optic neuritis
at disease onset predicts poor visual outcome in neuromyelitis optica
spectrum disorders. Mult Scler Relat Disord [Internet].
2020;41(March):102045. Available from:
https://doi.org/10.1016/j.msard.2020.102045
57. Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, Brown R, et
al. Prognostic factors and disease course in aquaporin-4 antibodypositive patients with neuromyelitis optica spectrum disorder from
the United Kingdom and Japan. Brain. 2012;135(6):1834–49.
58. Sepúlveda M, Armangué T, Sola-Valls N, Arrambide G, MecaLallana JE, Oreja-Guevara C, et al. Neuromyelitis optica spectrum
disorders: Comparison according to the phenotype and serostatus.
Neurol Neuroimmunol NeuroInflammation. 2016;3(3):1–9.
59. ERC et al F. Recomendações no tratamento da Esclerose Múltipla e
Neuromielite Óptica. Editora e Eventos Omnifarma, editor. São
Paulo: Departamento Científico de Neuroimunologia da ABN; 2016.
60. Kang H, Chen T, Li H, Xu Q, Cao S, Wei S. Prognostic factors and
disease course in aquaporin-4 antibody-positive Chinese patients with
acute optic neuritis. J Neurol. 2017;
61. Ambika S, Balasubramanian M, Theresa L, Veeraputhiran A,
90
Arjundas D. Aquaporin 4 antibody [NMO Ab] status in patients with
severe optic neuritis in India. Int Ophthalmol. 2015;
62. Waters P, Akman-demir G, Tu E, Jarius S, Mutlu M, Ku M, et al.
Prognostic implications of aquaporin-4 antibody status in
neuromyelitis optica patients. 2011;464–70.
63. Bichuetti DB, Falcão AB, Boulos F de C, Morais MM de, Lotti CB
de C, Fragomeni M de O, et al. The profile of patients followed at the
Neuroimmunology Clinic at UNIFESP: 20 years analysis. Arq
Neuropsiquiatr. 2015;73(4):304–8.
64. Shahmohammadi S, Doosti R, Shahmohammadi A,
Mohammadianinejad SE, Sahraian MA, Azimi AR, et al.
Autoimmune diseases associated with Neuromyelitis Optica
Spectrum Disorders: A literature review. Mult Scler Relat Disord.
2019;27(November 2018):350–63.
65. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: Clinical
predictors of a relapsing course and survival. Neurology.
2003;60(5):848–53.
66. Bergamaschi R, Ghezzi A. Devic’s neuromyelitis optica: Clinical
features and prognostic factors. Neurol Sci. 2004;
67. Papathanasiou A, Tanasescu R, Tench CR, Rocha MF, Bose S,
91
Constantinescu CS, et al. Age at onset predicts outcome in aquaporin4-IgG positive neuromyelitis optica spectrum disorder from a United
Kingdom population. J Neurol Sci. 2021;431(September):120039.
68. Wang KC, Lee CL, Chen SY, Lin KH, Tsai CP. Prominent brainstem
symptoms/signs in patients with neuromyelitis optica in a Taiwanese
population. J Clin Neurosci. 2011;18(9):1197–200.
69. Lu Z, Qiu W, Zou Y, Lv K, Long Y, You W, et al. Characteristic
linear lesions and longitudinally extensive spinal cord lesions in
Chinese patients with neuromyelitis optica. J Neurol Sci.
2010;293(1–2):92–6.
70. Wang Y, Zhang L, Zhang B, Dai Y, Kang Z, Lu C, et al.
Comparative clinical characteristics of neuromyelitis optica spectrum
disorders with and without medulla oblongata lesions. J Neurol.
2014;261(5):954–62.
71. Wang Y, Wu A, Chen X, Zhang L, Lin Y, Sun S, et al. Comparison
of clinical characteristics between neuromyelitis optica spectrum
disorders with and without spinal cord atrophy. BMC Neurol.
2014;14(1):1–7.
72. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and
progression of irreversible disability in multiple sclerosis: An
92
amnesic process. Brain. 2003;126(4):770–82.
73. Tintoré M, Rovira A, Rio J, Nos C, Grivé E, Téllez N, et al. Is optic
neuritis more benign than other first attacks in multiple sclerosis?
Ann Neurol. 2005;57(2):210–5.
74. Wu K, Wen LL, Duan R, Li Y, Yao Y, Jing L, et al. Triglyceride
Level Is an Independent Risk Factor in First-Attacked Neuromyelitis
Optica Spectrum Disorders Patients. Front Neurol.
2019;10(November):1–9.
75. S. Antonopoulos A, Margaritis M, Lee R, Channon K, Antoniades C.
Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular
Mechanisms and Lessons from the Recent Clinical Trials. Curr
Pharm Des. 2012;18(11):1519–30.
76. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH,
Feingold KR, et al. Effects of infection and inflammation on lipid and
lipoprotein metabolism: Mechanisms and consequences to the host. J
Lipid Res. 2004;45(7):1169–96. | pt_BR |